Regeneron's Lynozyfic (linvoseltamab) monotherapy achieved a 100% hematologic complete response in patients with second-line-plus systemic amyloid light chain (AL) amyloidosis in the Phase 1/2 LINKER-AL2 trial. The drug normalized free light chains by day 15 and showed rapid, durable responses, including improved kidney and heart function. This is significant as there are currently no approved treatments for relapsed or refractory AL amyloidosis. The Phase 2 portion of the trial is ongoing, aiming for regulatory approval.
The European Medicines Agency (EMA) has accepted Regeneron Pharmaceuticals' Marketing Authorization Application for Otarmeni (lunsotogene parvec), a gene therapy targeting biallelic OTOF variant-associated hearing loss, for accelerated assessment. Ot...
Regeneron Pharmaceuticals is under investigation by Pomerantz LLP following disappointing Phase 3 trial results for its melanoma treatment, which failed to show significant improvement over existing therapy. The news led to a nearly 10% drop in Regen...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
